BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10783478)

  • 1. Ex vivo expanded allogeneic cord blood progenitor cell transplantation with a non-myeloablative conditioning regimen would cure autoimmune diseases.
    Sastry PS
    Med Hypotheses; 2000 Mar; 54(3):423-4. PubMed ID: 10783478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for autoimmune diseases: nonmyeloablative conditioning regimens.
    Oyama Y; Traynor AE; Barr W; Burt RK
    Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S81-3. PubMed ID: 12931250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Umbilical cord blood as a source of stem cells].
    Bojanić I; Golubić Cepulić B
    Acta Med Croatica; 2006 Jun; 60(3):215-25. PubMed ID: 16933834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cord blood immunology and stem cell transplantation.
    Bradley MB; Cairo MS
    Hum Immunol; 2005 May; 66(5):431-46. PubMed ID: 15935881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens.
    Nash RA
    Bone Marrow Transplant; 2003 Aug; 32 Suppl 1():S77-80. PubMed ID: 12931249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.
    Molina A; Popplewell L; Kashyap A; Nademanee A
    Clin Transpl; 2000; ():317-42. PubMed ID: 11512326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.
    Huugen D; Schouten HC; Bos GM
    Neth J Med; 2002 May; 60(4):162-9. PubMed ID: 12164394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-myeloablative conditioning for hemopoietic stem cell transplantation--does it work?
    Cheong SK; Eow GI; Leong CF
    Malays J Pathol; 2002 Jun; 24(1):1-8. PubMed ID: 16329549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.
    Craddock C; Bardy P; Kreiter S; Johnston R; Apperley J; Marks D; Huber C; Kolbe K; Goulding R; Lawler M; Goldman J; Hughes T; Derigs G
    Br J Haematol; 2000 Dec; 111(3):797-800. PubMed ID: 11122140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
    Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
    Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.
    Tsirigotis P; Bitan RO; Resnick IB; Samuel S; Ackerstein A; Eladì S; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Shapira MY
    Haematologica; 2006 Jun; 91(6):852-5. PubMed ID: 16769592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.